Oramed Pharmaceuticals vs Rani Therapeutics
ORMP and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ORMP and RANI compare
Oramed Pharmaceuticals is the larger company, worth 2.1 times as much as Rani Therapeutics ($154M against $73.4M).
Oramed Pharmaceuticals pays a dividend yielding 6.7%; Rani Therapeutics does not pay one.
Oramed Pharmaceuticals scores higher on the StockData Score (12 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ORMP | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $154M | $73.4M |
| Share price | $3.71 | $0.526 |
| Change, 1 year | 50.2% | −75.2% |
| Change, 5 years | −86.0% | −98.5% |
| Beta (5Y) | 1.42 | 0.85 |
| Employees | 13 | 69 |
| StockData Score | ||
| Total score | 12 (better) | 2 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 1.1× | – |
| P/S | – | 11.1× |
| P/B | – | 2.2× |
| PEG | 0.04 | – |
| FCF yield | −2.1% (better) | −31.7% |
| Fair value | – | $0.366 |
| Margin of safety | – | −43.8% |
| Growth | ||
| Revenue growth (TTM) | – | 449% |
| Revenue growth, 5Y average | −5.8% | 28.7% (better) |
| Net income growth (TTM) | 230% | – |
| EPS growth (TTM) | 241% | – |
| EPS growth, 5Y average | 12.8% | – |
| Profitability | ||
| Operating margin | – | −530% |
| Net margin | – | −493% |
| FCF margin | – | −353% |
| Return on equity | 71.3% (better) | −249% |
| Return on invested capital | −8.5% (better) | −173% |
| Financial health | ||
| Interest coverage | – | −71.9× |
| Current ratio | 6.07 (better) | 5.26 |
| Altman Z-score | 1.55 (better) | −1.36 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 6.7% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 6.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 40.3% | 32.7% |
| Held by insiders | 23.9% | 30.6% |
| Insider net buying, 12 months | −$1.2M | $49.7K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.2% | 8.5% |
Go deeper
- ORMP stock overview
- ORMP income statement
- ORMP valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.